Comment on: “A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood”

@article{Li2016CommentO,
  title={Comment on: “A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood”},
  author={Guo-Fu Li and Xiao Gu and Guo Yao Yu and Shui-Yu Zhao and Qing-Shan Zheng},
  journal={Clinical Pharmacokinetics},
  year={2016},
  volume={55},
  pages={133-137}
}
Heart failure is associated with impaired cardiac output and tissue perfusion, thereby resulting in altered drug disposition and exposure [1–4]. In a recent issue of Clinical Pharmacokinetics, Rasool et al. [5] reported the worthwhile attempt to develop physiologically-based pharmacokinetic (PBPK) models for carvedilol in adult patients with chronic heart failure by incorporating pathophysiological alterations in hepatic and renal blood flows, and subsequently used the PBPK models to predict… CONTINUE READING
BETA

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Population-Based Mechanistic Prediction of Oral Drug Absorption

Masoud Jamei, David B. Turner, +4 authors Geoffrey T. Tucker
  • The AAPS Journal
  • 2009
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…